Cutaneous T-Cell Lymphoma, Mycosis Fungoides Subtype

Cobomarsen (SOLAR Clinical Trial)    Recruiting Internationally Fall 2018

➤ A Phase 2 clinical trial, SOLAR (MRG106-11-201), is designed to evaluate the efficacy and safety of the investigational drug, cobomarsen (MRG-106) for patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype.

Cobomarsen is an inhibitor of microRNA-155. microRNA-155 is believed to play an important role in the proliferation and survival of malignant cancer cells in certain types of blood cancer. In laboratory tests, inhibition of microRNA-155 in lymphoma cells reduces cancer cell proliferation.

Cobomarsen’s effect on mycosis fungoides will be compared in this study with the effect of vorinostat, which is a drug that has been approved in the US, Canada and Australia for the treatment of CTCL. Data from this clinical trial may allow submission of a marketing application for use of cobomarsen in the treatment of mycosis fungoides.

More information on this study can be found here.

More information about cobomarsen can be found here.